Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors.
Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday.
“We welcome Joao and Myoung to our board of directors at this exciting stage in Tandem’s evolution,” Tandem President and CEO John Sheridan said in a news release. “Joao’s extensive international experience brings tremendous value to our company as we continue to expand our global reach, and Myoung’s strategic experience in leading-edge consumer technology at large companies will be invaluable as we advance our product pipeline.”
Cha has picked up experience totaling more than 17 years across the healthcare value chain and currently serves as chief strategy officer of Carbon Health, where he leads the omnichannel care model and the device-enabled home care operations.
Before Carbon Health, which he joined in June 2021, Cha was head of health strategic initiatives at Apple for nearly six years, developing and leading product initiatives and global strategic partnerships. He’s also held roles with the West Coast Strategy and Corporate Finance Practice and the Healthcare Investor Practice at McKinsey & Co.
Malagueira joins Tandem’s board with more than 25 years of experience in diabetes, medical devices and diagnostics at global corporations.
He currently serves as VP for three divisions at Hologic and has responsibility for the company’s entire portfolio in the EMEA. Before this role at Hologic, which he assumed in January 2019, Malagueira was international VP for EMEA and Canada for Hologic’s diagnostics solutions division, a position he held for more than three years.
Malagueira also spent more than 15 years at Johnson & Johnson in commercial leading roles across EMEA. He led turnarounds and market share growth for the diabetes solutions businesses at J&J, LifeScan and Animas.